These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19581612)

  • 21. Statistics and drug utilization: are prescribing rates really that high?
    Morgan S
    CMAJ; 2001 Nov; 165(11):1507-8. PubMed ID: 11762577
    [No Abstract]   [Full Text] [Related]  

  • 22. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Product labeling and pharmacoeconomic information.
    Morris LA
    Am Heart J; 1999 May; 137(5):S78-80. PubMed ID: 10220603
    [No Abstract]   [Full Text] [Related]  

  • 23. Orphan Drug Development in Cardiovascular Medicine.
    Khan MS; Vaduganathan M; Butler J
    Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006509. PubMed ID: 32552063
    [No Abstract]   [Full Text] [Related]  

  • 24. HOPE study impact on ACE inhibitors use.
    Hemels ME; Bennett HA; Bonari L; Han D; Traverso ML; Einarson TR
    Ann Pharmacother; 2003 May; 37(5):640-5. PubMed ID: 12708937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prescription drugs: recent trends in utilization, expenditures, and coverage.
    Sethi RC
    EBRI Issue Brief; 2004 Jan; (265):1-35. PubMed ID: 14969223
    [No Abstract]   [Full Text] [Related]  

  • 26. Current trends in cardiovascular therapy.
    Palmaz JC
    J Cardiovasc Surg (Torino); 2009 Feb; 50(1):3-6. PubMed ID: 19179985
    [No Abstract]   [Full Text] [Related]  

  • 27. Chronic catastrophes: exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia, Canada.
    Hanley GE; Morgan S
    Soc Sci Med; 2009 Mar; 68(5):919-24. PubMed ID: 19135288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defying the prescription. Forget forecasts--drug sales soar under managed care.
    Hensley S
    Mod Healthc; 1998 Apr; 28(15):42. PubMed ID: 10178321
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug treatment and cost of cardiovascular disease in Australia.
    Ademi Z; Liew D; Chew D; Conner G; Shiel L; Nelson M; Soman A; Steg G; Bhatt DL; Reid C;
    Cardiovasc Ther; 2009; 27(3):164-72. PubMed ID: 19689615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Merck Serono targets convenient, affordable medicines for patients at risk.
    Cardiovasc J Afr; 2009; 20(1):77. PubMed ID: 19287822
    [No Abstract]   [Full Text] [Related]  

  • 31. [Pharmacoeconomic indicators of cardiovascular drug utilization in the Republic of Croatia and city of Zagreb in 2008].
    Stimac D; Stambuk I
    Acta Med Croatica; 2010 Dec; 64(5):383-90. PubMed ID: 21692262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Condition-specific disease treatment in dialysis patients: utilization, costs, and guideline and policy imperatives.
    Straube BM
    Am J Kidney Dis; 2012 May; 59(5):595-7. PubMed ID: 22507647
    [No Abstract]   [Full Text] [Related]  

  • 33. Proceedings of a symposium: economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful health economic study for the pharmaceutical industry?
    Gagnon JP
    Am Heart J; 1999 May; 137(5):S62-6. PubMed ID: 10220599
    [No Abstract]   [Full Text] [Related]  

  • 34. [Economic or medical innovations: that is the question!].
    Freitag MH; Wohlgemuth WA
    Med Klin (Munich); 2006 Jul; 101(7):590-1; author reply 591-3. PubMed ID: 16897896
    [No Abstract]   [Full Text] [Related]  

  • 35. The Medicare drug benefit (Part D) and treatment of heart failure in older adults.
    Donohue JM; Zhang Y; Lave JR; Gellad WF; Men A; Perera S; Hanlon JT
    Am Heart J; 2010 Jul; 160(1):159-65. PubMed ID: 20598987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cardiologies reflect on cost cuts. Waste with heart drugs?].
    Schumacher B
    MMW Fortschr Med; 2003 Sep; 145(38):4-5. PubMed ID: 14603669
    [No Abstract]   [Full Text] [Related]  

  • 37. Where are we going with drugs to treat MS? Will cost continue to increase?
    Oger J; AlKhawajah M
    Can J Neurol Sci; 2010 May; 37(3):305-8. PubMed ID: 20481262
    [No Abstract]   [Full Text] [Related]  

  • 38. [Increasing drug costs. The society's drug expenditures are strongly increasing. If this trend continues we have to make other priorities].
    Andreasen J
    Ugeskr Laeger; 2003 Jul; 165(29):2873-6. PubMed ID: 12908355
    [No Abstract]   [Full Text] [Related]  

  • 39. Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D.
    Frankenfield DL; Weinhandl ED; Powers CA; Howell BL; Herzog CA; St Peter WL
    Am J Kidney Dis; 2012 May; 59(5):670-81. PubMed ID: 22206743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increasing use of disease modifying drugs for MS in Canada.
    Rotstein DL; Mamdani M; O'Connor PW
    Can J Neurol Sci; 2010 May; 37(3):383-8. PubMed ID: 20481274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.